Based on these findings, simultaneously inhibiting S-RBD and NRP1 may result in a synergistic effect on the inhibition of virus infection, and dual S-RBD/NRP1-targeting inhibitors may become a potential therapeutic approach to preventing SARS-CoV-2 infection. This evidence concerns the gene NRP1 and viral infectious disease.